Search

Compugen Ltd

Cerrado

2.12 0.47

Resumen

Variación precio

24h

Actual

Mínimo

2.1

Máximo

2.12

Métricas clave

By Trading Economics

Ingresos

663K

-7M

Ventas

426K

2.6M

P/B

Media del Sector

6.079

47.946

BPA

-0.07

Margen de beneficios

-269.254

Empleados

75

EBITDA

665K

-7M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+112.26% upside

Dividendos

By Acuity

Próximas Ganancias

9 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-6.3M

219M

Apertura anterior

1.65

Cierre anterior

2.12

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 oct 2026, 23:51 UTC

Canada's Housing Starts Data Set for Release Amidst Weak Employment Figures, Forecasting 230K Units and Cautious Market Sentiment.

10 oct 2026, 23:41 UTC

Market Awaits NY Empire State Manufacturing Index Release Amid Cautious Optimism and Broader Economic Concerns on October 15, 2026.

10 oct 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index for October 2026 set to release with optimistic growth forecast amid inflation concerns and upcoming earnings reports.

10 oct 2026, 23:41 UTC

Core Producer Prices Expected to Rise 0.3% in September, Amid Cautious Market Sentiment and Inflation Concerns Ahead of Key Economic Reports

10 oct 2026, 23:41 UTC

US Producer Price Index Expected to Rise 0.5% Amidst Deteriorating Consumer Confidence and Inflation Concerns Ahead of October Release

10 oct 2026, 23:31 UTC

Australia's upcoming employment data release on October 15 is crucial, following a significant decline in full-time jobs and amid cautious economic sentiment influenced by global market fluctuations.

10 oct 2026, 23:31 UTC

Australia's Unemployment Rate Expected to Rise to 4.6% in September, Sparking Concerns Over Labor Market Stability Amid Global Economic Volatility

10 oct 2026, 23:31 UTC

Australia's Employment Change Report on October 15 Expected to Show Job Growth Amid Global Labor Market Concerns.

10 oct 2026, 23:21 UTC

US CPI Release on October 14 Sparks Caution Among Investors Amid Declining Consumer Sentiment and Inflation Concerns

10 oct 2026, 23:21 UTC

U.S. CPI data release on October 14 expected to show inflation rise to 3.6%, amid declining consumer confidence and fears of Federal Reserve tightening ahead of midterm elections.

10 oct 2026, 23:21 UTC

Core Inflation Rate Release on October 14, 2026, Expected to Rise by 0.2%, Influencing Federal Reserve Interest Rate Decisions Amidst Cautious Market Sentiment and Consumer Concerns Over Rising Costs.

10 oct 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.6% in September Amid Consumer Confidence Decline and Geopolitical Tensions, Influencing Federal Reserve Policy Discussions

10 oct 2026, 23:21 UTC

Market Anticipates CPI Release Amid Rising Inflation Concerns and Mixed Investor Sentiment

10 oct 2026, 23:21 UTC

Core Inflation Rate for September 2026 Expected to Rise Slightly to 2.5%, Heightening Market Caution Amidst Rising Consumer Sentiment and Geopolitical Tensions.

10 oct 2026, 23:11 UTC

Brazil's Retail Sales Data Release on October 15 Expected to Reveal Consumer Spending Trends Amid Cautious Market Sentiment.

10 oct 2026, 23:01 UTC

Macro News

The Dow Jones Index (US) is trading roughly flat in after-market hours amid concerns over semiconductor stocks and heightened geopolitical tensions.

10 oct 2026, 22:51 UTC

Japan's Machinery Orders MoM data for August, set to release on October 14, is expected to show a modest 2.5% growth amid mixed manufacturing sentiment and concerns over softening demand.

10 oct 2026, 22:51 UTC

Australia's NAB Business Confidence report set for October 13 reveals cautious market sentiment amid declining confidence and rising costs, raising concerns over economic stability.

10 oct 2026, 22:51 UTC

RBA Meeting Minutes on October 13, 2026, Expected to Influence Interest Rate Decisions Amid Inflation Concerns and Global Economic Factors.

10 oct 2026, 22:51 UTC

The Nikkei 225 Index is roughly flat in after-market trading, holding steady since Friday's close amid positive sentiment ahead of upcoming corporate earnings reports.

10 oct 2026, 22:41 UTC

Singapore's Q3 2026 GDP Growth Rate Release on October 14 Sparks Cautious Optimism Amid Economic Recovery Signs and Mixed Asian Market Sentiments.

10 oct 2026, 22:41 UTC

U.S. 30-Year Mortgage Rates Hit 7.49% Amid Rising Treasury Yields and Inflation Concerns, Forecasting Continued Upward Pressure on Housing Market Demand

10 oct 2026, 22:31 UTC

Brazil's Central Bank to Release Key Interest Rate Insights Amid Rising Inflation on October 13, 2026.

10 oct 2026, 22:21 UTC

South Korea's Unemployment Rate Release on October 15 Expected to Reflect Labor Market Resilience Amid Global Economic Pressures.

10 oct 2026, 22:01 UTC

Spain's Consumer Confidence Index set for October 13 release amid cautious sentiment due to inflation and geopolitical tensions.

10 oct 2026, 21:31 UTC

Italy's Balance of Trade data set for October 16, with a forecasted €7.5 billion surplus amid cautious sentiment following disappointing industrial production figures.

10 oct 2026, 21:31 UTC

UK Retail Sales Monitor YoY for September 2026 Expected to Show Modest 0.7% Increase Amid Cautious Consumer Sentiment and Inflation Concerns

10 oct 2026, 20:41 UTC

India's Inflation Rate YoY Release on October 12, 2026, Expected to Reflect Ongoing Energy Price Pressures Amid Optimistic Market Sentiment.

10 oct 2026, 20:31 UTC

API Crude Oil Stock Change Report on October 14, 2026, to Reflect Inventory Fluctuations Amid Geopolitical Tensions and Market Caution Ahead of Key Inflation Data.

10 oct 2026, 20:31 UTC

Fed Governor Barkin's Upcoming Speech Sparks Cautious Market Sentiment Amid Inflation Concerns and Key Economic Data Releases.

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

112.26% repunte

Estimación a 12 Meses

Media 4.5 USD  112.26%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.